Premium
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Author(s) -
Derakhshani Afshin,
Rezaei Zohreh,
Safarpour Hossein,
Sabri Morteza,
Mir Atefeh,
Sanati Mohammad Amin,
Vahidian Fatemeh,
Gholamiyan Moghadam Ali,
Aghadoukht Ali,
Hajiasgharzadeh Khalil,
Baradaran Behzad
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29216
Subject(s) - trastuzumab , medicine , breast cancer , oncology , blockade , human epidermal growth factor receptor 2 , drug resistance , cancer , monoclonal antibody , pharmacology , receptor , antibody , immunology , biology , microbiology and biotechnology
Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2‐positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects.